A major European event at the heart of bioprocessing innovation
BioProcess International Europe (BPI Europe) will take place on April 29–30, 2026, at the VIECON – Vienna Congress & Convention Center in Vienna. The event brings together leaders from biopharma, biotech, CDMOs, and academia. All participants share the same objective: turning biological innovation into scalable and reliable production systems.
Unlike purely academic conferences, BPI Europe focuses on industrial challenges. It covers upstream and downstream processing, cell line development, and manufacturing strategies. As a result, it creates a unique environment where science meets industrial execution.
The industrial bottleneck in modern cell-based applications
Advanced cell systems are transforming research. However, scaling them remains difficult. Fragile cells such as stem cells, immune cells, and organoids require precise conditions. Traditional systems struggle to provide this control.
Conventional bioreactors rely on mechanical agitation. These systems generate increasing shear stress as volume grows. This stress damages cells, reduces viability, and alters biological functions. At the same time, gradients in oxygen and nutrients create heterogeneous environments.
Because of these limitations, many processes fail to scale efficiently. Companies often rely on scale-out strategies instead of true scale-up. This approach increases costs and limits industrial deployment .
A shift toward controlled and scalable biological systems
The industry is evolving. Engineers now design systems that integrate both biological and physical parameters. This shift changes how cell culture platforms are developed.
First, precise control of the microenvironment has become essential. Second, reproducibility across scales is now a regulatory requirement. Third, scalability must not require process redesign. Finally, 3D systems demand homogeneous conditions to remain functional.
These constraints are redefining bioprocessing standards. As a result, new technologies must address both biological sensitivity and industrial robustness.
SoftXS™: a new approach to cell culture engineering
Cellura introduces SoftXS™ as an alternative to conventional bioreactors. The system uses a bladeless mixing approach based on controlled chaotic flow. This design avoids the turbulence created by impellers.
As a result, cells remain in homogeneous suspension without exposure to damaging forces. The system reduces shear stress significantly while maintaining efficient mixing.
Another key advantage lies in scalability. SoftXS™ maintains consistent conditions across volumes. Processes developed at small scale can therefore transition directly to larger systems without redesign.
In addition, the platform integrates easily into existing workflows. Its compact format allows rapid deployment in both research and industrial environments.
Demonstrated performance across multiple cell types
Experimental data confirm the performance of SoftXS™. The system supports high-efficiency expansion of induced pluripotent stem cells while preserving pluripotency. It also enables the amplification of immune cells with high viability.
Furthermore, SoftXS™ supports the formation of organoids and spheroids under controlled conditions. It maintains homogeneous aggregate size and prevents unwanted fusion. The system also ensures gentle suspension of microcarriers at low rotational speeds.
These results demonstrate a key advantage. SoftXS™ combines biological integrity, reproducibility, and scalability in a single platform .
Applications aligned with industry needs
SoftXS™ addresses several strategic domains. In cell therapy, it enables reliable expansion of stem cells. In immunotherapy, it supports scalable production of functional immune cells.
In oncology, the system allows the generation of reproducible 3D tumor models. In bioproduction, it simplifies the transition toward GMP processes. It also opens opportunities in emerging fields such as cultivated meat and environmental biology.
Across all these applications, the same requirement applies: scalable systems that preserve cell functionality.
Cellura at BPI Europe
Cellura will participate in BPI Europe to engage with the bioprocessing community. The event provides an opportunity to discuss industrial challenges and present new approaches to cell culture.
Cellura will be present in Vienna alongside Baptiste Roumezi, CTO. The team will exchange with partners, researchers, and industry stakeholders interested in scalable and controlled cell culture systems.
Conclusion
Bioproduction is entering a new phase. Scientific innovation alone is no longer sufficient. Industrial scalability has become the key challenge.
BPI Europe highlights this transition. The event brings together the actors shaping the future of bioprocessing.
Technologies such as SoftXS™ demonstrate how engineering can solve biological constraints. By reducing shear stress and improving homogeneity, they enable more reliable and scalable systems.
This convergence between biology and engineering will define the next generation of cell-based applications.
About the event
More information about BPI Congress is available on the official website: https://informaconnect.com/bpieurope/
For further information or to arrange a meeting:
Email: contact@cellura.io
